Correlation Between The Hematological Toxicity And Serum Sex Hormone Levels In Patients With Non-small-cell Lung Cancer

Objective and backgroundLung cancer is the most common cancer and the first leading cause of cancerdeaths in the world. About80%-85%of total lung cancer patients are NSCLC patients.Chemotherapy is one of the three methods in treating malignant tumor, but there is nometabolic fundamental differences between tumor cells and the normal cells, so thechemotherapy drugs have a risk of damage to the normal tissue. Hematologic toxicityis one of the most common adverse reactions to chemotherapy. At present, theoccurrence and severity of blood toxicity is relate to anticancer drug types, dosage,treatment periodicity, hematopoietic cell renewal rate and individual differences. Inrecent years, more and more researches show that gender and hematological toxicityof chemotherapy has a certain correlation. But its mechanism is still not clear. Changeof serum sex hormone levels may be the factor affecting hematologic toxicity ofchemotherapy. However, the present studies are still limited, it needs more trials andfurther study to the mechanism of gender factor influenced hematological toxicity,providing basis for prevention of hematological toxicity and reasonable treatment ofpatients with cancer. This study aims to survey with the incidence of chemotherapyhematologic toxicities and serum sex hormone levels in NSCLC patients, to observethe relationship between chemotherapy hematologic toxicity and serum sex hormonelevels, providing basis for prevention of chemotherapy blood toxicity and reasonabletreatment of NSCLC patients. Method68newly diagnosed NSCLC patients were collected in Shandong Cancer Hospitalfrom2012February to2012October, Serum luteinizing hormone (LH), estradiol (E2),progesterone (P) and follicle-stimulating hormone (FSH) of patients with morningfasting venous blood. Measure1time in each cycle before the start of and after thechemotherapy. Recording the occurion of hematologic toxicity, in accordance withthe standard chemotherapy toxicity assessment of WHO, dividing into0-Ⅳ degrees,the patients were divided into2groups,0degrees is no hematological toxicity group,Ⅰ-Ⅳ degree is toxic group of hematology. Data processing is performed using SPSS16.0medical statistical analysis, and P <0.05is defined as there is statisticalsignificance in difference.Result1. There are differences in the level of serum FSH between men and women, serumlevel was higher in females than in males(P<0.05). There is no significant differencein age, pathological type, stage, body surface area group(P>0.05); influencing factorsof serum P level were stage and pathological type (P<0.05), there is nosignificant difference in age, body surface area group(P>0.05); pathological typeinfluences the serum level of LH(P<0.05), there were no significant differences in theage, stage and body surface area group (P>0.05); serum FSH level was relate topathological type and body surface area(P<0.05), there were no significancedifferences in the stage and age group(P>0.05).2. The serum levels of E2, LH, FSH, P were changed in patients after chemotherapy,but the change of E2, P were no statistical significance(P>0.05).3. The change of the serum levels of FSH, LH after chemotherapy in patients withhematologic toxicity had statistical significance (P <0.05), there was no significantchange of serum levels of E2, P (P>0.05); the serum level of FSH was increased inpatients with hematological toxicity after chemotherapy (P <0.05), but the serumlevels of E2, P, LH had no significant change (P>0.05).4. There is no correlation between hematologic toxicity and the serum levels of E2,LH, FSH, P, and there is no significant difference between the two groups (P>0.05).But the serum level of P, FSH in patients without hematological toxicityis higher than that of patients with hematologic toxicity, there were significant differences (P＜0.05).Conclusion1. There is different in the serum level of FSH between men and women, but thereis no significant difference in the serum level of E2、LH、P.2. The serum level of E2, LH, FSH, P were no significant change.3. The serum level of LH, FSH were changed in patients with hematological toxicityafter chemotherapy compared with those before, the change of the serum levelsof E2, P after chemotherapy was no statistical significance. In nohematological toxicity group, the serum level of FSH was increased afterchemotherapy, but the serum levels of E2, P, LH had no obvious change.4. No correlation between hematologic toxicity and the serum levels of E2, LH,FSH, P and he serum levels of E2, LH after chemotherapy, and the serum levelof them were no significant differences between the two groups, but the serum levelof P、 FSH in patients without hematological toxicity was higher than that ofpatients with hematologic toxicity after chemotherapy, there were significantdifferences.Further studies is need on the correlation.